Kyongbo Pharmaceutical Co., Ltd

Total Valuation

Kyongbo Pharmaceutical Co., Ltd carries a market capitalization of 131.73B, placing it among publicly traded companies globally. Its enterprise value stands at 304.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Kyongbo Pharmaceutical Co., Ltd currently has 23.91M shares outstanding.

Valuation Ratios

Kyongbo Pharmaceutical Co., Ltd trades at a trailing price-to-earnings ratio of 511.58. The price-to-sales ratio is 0.64, and the price-to-book ratio stands at 1.58.

Enterprise Valuation

On an enterprise value basis, Kyongbo Pharmaceutical Co., Ltd trades at an EV/EBITDA multiple of 74.12 and an EV/FCF ratio of 4.87. The EV/Sales ratio of 1.13 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 74.12 provides insight into valuation relative to core operating earnings.

Financial Position

Kyongbo Pharmaceutical Co., Ltd maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Kyongbo Pharmaceutical Co., Ltd posts a return on equity of 0.31 and a return on invested capital of 0.77.

Taxes

Over the trailing twelve months, Kyongbo Pharmaceutical Co., Ltd has paid 342.31M in income taxes, reflecting an effective tax rate of 50.51.

Stock Price Statistics

Kyongbo Pharmaceutical Co., Ltd's stock has gained approximately 1.10092% over the past 52 weeks. The 50-day moving average sits at 6,800.40, while the 200-day moving average is 6,063.20.

Income Statement

Over the trailing twelve months, Kyongbo Pharmaceutical Co., Ltd generated 269.64B in revenue and converted that into 335.39M in net income, yielding earnings per share of 14.00. EBITDA reached 4.11B, while operating income came in at 4.11B.

Balance Sheet

Kyongbo Pharmaceutical Co., Ltd holds 9.95B in cash and equivalents against 143.03B in total debt, resulting in a net debt position of 135.15B. Total book value stands at 108.64B, with working capital of -10.01B providing operational flexibility.

Cash Flow

Kyongbo Pharmaceutical Co., Ltd produced 11.23B in operating cash flow over the past twelve months. After subtracting -51.37B in capital expenditures, free cash flow totaled -40.13B - equivalent to -1,674.82 per share.

Margins

Kyongbo Pharmaceutical Co., Ltd operates with a gross margin of 39.19, reflecting its pricing power and cost economics. The operating margin of 1.52 and net profit margin of 0.12 provide insight into operational efficiency.

Dividends & Yields

Scores

Kyongbo Pharmaceutical Co., Ltd posts an Altman Z-Score of 1.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.